FLORHAM PARK, NJ: Pharmaceutical company Shionogi has selected Lippe Taylor as AOR for its Osphena brand following a competitive review. Ketchum was the incumbent on the account.
Lippe Taylor went up against at least seven agencies in the RFP for Osphena, which is a non-estrogen oral tablet used to treat painful intercourse due to menopause.
It is understood that the firm is working on a program with a seven-figure budget.
Osphena previously worked with Ketchum for less than a year, a brand representative confirmed. The relationship ended last fall.
Ketchum representatives did not respond to inquiries seeking comment.
"We felt immediate chemistry with the Lippe Taylor team," said Heidemarie Schnell, director of marketing and Osphena consumer and PR at Shionogi, in an emailed statement. "Their extensive experience communicating with women, along with their media expertise, really stood out to us."
"At Shionogi, we expect strategic and novel thinking and expect the same from our agency partners," Schnell added. "We are confident that Lippe Taylor can deliver that for Osphena."
Lippe Taylor, which was brought on earlier this month, will lead consumer and professional PR for the brand, focusing on educating the media and telling the brand’s story. The firm will also help Osphena with strategic alliances and patient advocacy efforts. In supporting Osphena’s women’s health campaign, Lippe Taylor will work to educate women to help them make the best decisions for their bodies.
Other Shionogi brands include Claritin, Cymbalta, and Crestor.